Overview

Radiation Therapy Plus Amifostine in Treating Patients With Primary Prostate Cancer

Status:
Completed
Trial end date:
2001-06-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Amifostine may protect normal cells from the side effects of radiation therapy. PURPOSE: Phase II trial to study the effectiveness of radiation therapy plus amifostine in treating patients with primary prostate cancer.
Phase:
Phase 2
Details
Lead Sponsor:
University of Arizona
Collaborator:
National Cancer Institute (NCI)
Treatments:
Amifostine